Carleton JC Hsia, PhD
Founder & CEO
AntiRadical Therapeutics LLC
Dr. Carleton Hsia was a Professor of Pharmacology at the University of Toronto, School
of Medicine. His invention of a first generation blood substitute led to the formation of
Hemosol, Inc., a New York and Toronto publicly traded biotech company.
Dr. Hsia recently founded AntiRadical Therapeutics in 2016. He is the recipient of
numerous peer-reviewed NIH SBIR grants. His most recent invention of
macromolecular superoxide dismutase (SOD3) is for treatments in the areas of
oncology, inflammation, blood disorders and the central nervous system.